Your browser version may not work well with NCBI's Web applications. More information here...
1: J Am Acad Dermatol. 1985 May;12(5 Pt 1):857-62.Links

Plaquenil-induced erythroderma.

Slagel GA, James WD.

A patient who developed exfoliative erythroderma 11 days after the initiation of hydroxychloroquine treatment for psoriatic arthritis is presented. Our experience with her and the continued controversy regarding the incidence of adverse reactions in psoriatic patients to antimalarials prompted a detailed review of the literature. We conclude that the use of antimalarials in patients with psoriasis is associated with a high incidence of severe cutaneous adverse reactions. These medications should not be used in psoriatic patients if other less toxic, effective therapies are available.

PMID: 3159760 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Hydroxychloroquine (Plaquenil® )

    Hydroxychloroquine is in a class of drugs called antimalarials. It is used to prevent and treat acute attacks of malaria. It is also used to treat discoid or systemic lupus erythematosus and rheumatoid arthritis in patie...

  • Source: AHFS Consumer Medication Information

Recent Activity